Risk of Thromboembolic Events in Patients with Non-Valvular Atrial Fibrillation After Dabigatran or Rivaroxaban Discontinuation - Data from the Ljubljana Registry.

Nina VeneAlenka MavriMirjam GubenšekGregor TratarTjaša Vižintin CudermanMaja Pohar PermeAles Blinc

Published in: PloS one (2016)

Dabigatran and rivaroxaban offered good protection against thromboembolic events during treatment, but interruption of NOAC treatment increased the short-term thromboembolic risk more than 20-fold.

Keyphrases

atrial fibrillation
oral anticoagulants
left atrial
catheter ablation
left atrial appendage
direct oral anticoagulants
heart failure
electronic health record
big data
coronary artery disease
left ventricular
acute coronary syndrome
smoking cessation
replacement therapy